BPC-157 Oral vs Injectable (2026): What the Studies Actually Used, and What We Still Don’t Know

Research Guides · 13 min read · Updated October 2026

Why BPC-157 is the “oral peptide” exception

Most peptides are useless by mouth. Stomach acid and digestive enzymes break them into amino acids long before they can do anything. A 2025 review of BPC-157 makes the general point that poor peptide stability usually “precludes” oral delivery.¹ That is why insulin, GLP-1 drugs and most research peptides are studied as injectables, and why the few oral peptide drugs depend on special absorption technology.

BPC-157 is pitched as different for a simple reason: it was first described in 1993 as a fragment of a protein found in human gastric juice.¹ If a peptide lives in the stomach, the reasoning goes, it ought to survive there. Sikiric’s group has built a large literature on that idea, describing BPC-157 as working “using whatever way of application (parenteral or per-oral).”²

That’s the origin of the oral-vs-injectable debate. To see how much of it holds up, look at what the studies actually did. If you’re new to the compound, start with What is BPC-157?

Which routes the published studies used

Across the literature, BPC-157 has been given to animals in a surprising number of ways. A 2025 literature review lists intraperitoneal, intragastric, subcutaneous, intramuscular, intravenous, topical and intra-articular routes, and notes that alcohol-injury studies compared intraperitoneal with intragastric dosing.¹ Here are three well-documented examples where oral (drinking water) and injected routes appear side by side.

Short-bowel syndrome in rats (2009)

Rats had most of their small bowel removed, then received BPC-157 either in drinking water or by daily intraperitoneal injection. With either route, the treated rats gained weight above their pre-surgery values, showed adaptive changes in villus height and crypt depth, and had stronger surgical joins than controls.⁵

Colocutaneous fistulas in rats (2008)

A fistula is an abnormal channel, here between colon and skin. BPC-157 in drinking water and BPC-157 by intraperitoneal injection both sped up closure of the colon and skin defects. They also beat sulphasalazine, which was only moderately effective.⁶

Ligament healing in rats (2010)

In a 90-day study of medial collateral ligament (MCL) transection, BPC-157 was given three ways: intraperitoneally, in drinking water, or as a cream applied at the injury. The authors reported consistent improvements in function, biomechanics and tissue appearance with all three.⁷

Notice the pattern. In Sikiric-group papers, the oral arm usually “works” about as well as the injected arm. That’s interesting, but these are small rat studies, mostly from one research group, and “worked in a rat drinking it” is a long way from “absorbed in a person swallowing a capsule.” A 2019 review cautioned that many studies come from the same laboratory and that results must be extrapolated carefully.⁸

Route by research area (table)

This table summarizes which routes were used in representative published studies. It describes study methods only, not recommendations.

The takeaway: gut research is where oral administration has the strongest rationale and the most data, since the peptide is delivered straight to the tissue being studied. Tendon and muscle research leaned on systemic injection or local application. For background on those research areas, see our overviews on gut conditions in Canada and tendonitis treatment in Canada, which cover the approved medical options.

The gastric juice stability claim

You’ll see this line on almost every oral BPC-157 product page: “stable in human gastric juice for over 24 hours.” Where does it come from?

It is the Sikiric group’s own description. Their 2024 review states that BPC-157 is “not destroyed in human gastric juice for more than 24 h,” citing their earlier work.² Other authors repeat it secondhand. The 2022 rat-and-dog pharmacokinetic paper, for example, mentions gastric-juice resistance in its introduction, but did not test it.³

Now the complication. A US patent granted in 2017 to the Slovenian company Diagen (inventor Rudolf Rucman) reports stability tests in artificial gastric juice at 37 °C.⁴ In the patent’s tables, the standard BPC-157 acetate content fell from 100 to about 21 within 30 minutes at pH 2.0, and to about 0.08 after five hours at pH 3.0. The arginine-salt version held up much better at pH 3.0 (about 85 after five hours) and at pH 4.0, but at pH 2.0 it also fell fast (about 30 at 30 minutes).⁴

Stomach survival is also only step one. A peptide still has to cross the gut wall and survive the liver to reach the bloodstream, and none of that has been measured for oral BPC-157 in humans.

Acetate vs arginate salts

Peptides are sold as salts. The counter-ion (the small molecule paired with the peptide) affects stability, solubility and handling.

• BPC-157 acetate is the standard research form and the form most studies describe. When the FDA’s compounding advisory committee voted on BPC-157 in July 2026, the recommendation covered the “free base and acetate formulations.”¹²
• BPC-157 arginate (an arginine salt) is described in the Diagen patent, which names the di-L-arginine salt as preferred.⁴ Beyond the gastric data above, the patent reports that after 388 hours in water at 50 °C the arginine salt retained about 99% of its content versus about 21% for the acetate. After 90 days as a solid at 50 °C and 65% humidity, the figures were about 99% versus about 86%.⁴

Two cautions. First, better shelf and heat stability is not the same thing as better absorption. The patent only says improved membrane transfer is “realistic to expect,” which is a prediction, not a measurement.⁴ Second, most of the rodent studies people quote were not done with the arginate. When a capsule is marketed as “arginate, so it works orally,” it is borrowing results from studies of a different salt.

Bioavailability: what is actually measured

Bioavailability is the share of a dose that reaches the bloodstream intact. For BPC-157, here is everything solid we could find:

• Rats and dogs, intramuscular (2022): absolute bioavailability of about 14–19% in rats and 45–51% in beagle dogs. The parent peptide’s elimination half-life was under 30 minutes, and it was quickly broken down into small fragments and then single amino acids, mainly excreted in urine and bile.³
• Oral bioavailability: not measured in that study. It tested only intravenous and intramuscular dosing.³
• Human pharmacokinetics: a 2025 review calls the available human PK data “rather scanty.”¹

So even for injection, animal bioavailability varied about threefold between species, and the peptide was gone from plasma within minutes. We could not find a published oral bioavailability figure for BPC-157 in any species. If a website quotes an “oral bioavailability” percentage, ask where it was measured.

Human data on any route

Here is the complete picture of published or registered human BPC-157 work we could verify:

The only planned human oral study, the Phase I trial, never reported results.¹ The only formal human safety data come from an IV pilot in two people.⁹ That’s the reason a 2025 systematic review concluded that BPC-157’s in-human safety “remains unknown.”¹³ For what has been reported about tolerability, see BPC-157 side effects.

Why oral capsules are a quality wildcard

Put the pieces together and you can see why we call “BPC-157 capsules” a wildcard. This isn’t a claim that every capsule is fake. It’s that almost every variable is unknown.

• Unknown salt. Acetate and arginate behave very differently in acid and heat in the patent data,⁴ and labels often don’t say which one is inside.
• Unknown content after manufacturing. The patent shows acetate content dropping sharply in warm water over time.⁴ Capsule production, fillers, moisture and months on a shelf are all chances for degradation, and a finished capsule is hard to test.
• No absorption data. Even a perfect capsule has no published human oral bioavailability behind it.^3,1
• Not a supplement ingredient. The US Department of Defense’s Operation Supplement Safety states plainly that “BPC-157 is not a dietary ingredient” and is an unapproved drug.¹⁴ Products sold as supplements anyway are outside normal supplement quality systems.
• Harder to verify. A lyophilized vial can be checked by HPLC and mass spectrometry against a batch COA. With a capsule, you also need to know the fill weight, the excipients and how stable the blend is, and those are rarely documented.

For how to judge any peptide product, see How to spot fake peptides and How to read a peptide COA.

Legal status in Canada

Health Canada’s August 1, 2025 advisory states that “injectable peptides are regulated as prescription drugs in Canada” and that “selling unauthorized drugs is illegal in Canada.” BPC-157 appears on its list of seized products.¹⁵ The advisory tells consumers to look for an eight-digit DIN, NPN or DIN-HM on health products. We are not aware of any BPC-157 product authorized in Canada, and Health Canada says none of the seized products had been authorized.

South of the border, an FDA advisory committee voted 8–6 (one abstention) in July 2026 to recommend adding BPC-157 to the 503A compounding bulk list for ulcerative colitis. The next step is rulemaking that could run into 2027 or longer.¹² That decision has no effect on Canadian law, and it isn’t an approval. BPC-157 is also on WADA’s prohibited list (class S0) for athletes.^13,14 For more, see Is BPC-157 banned?. For any health concern, talk to your doctor or pharmacist.

Oral BPC-157 myths

“Myth: Oral BPC-157 is proven to work as well as injections.”

Some rat studies reported similar effects from drinking water and intraperitoneal injection.^5,6,7 No human study has compared routes, and we found no published oral bioavailability measurement in any species.³

“Myth: BPC-157 is stable in stomach acid, full stop.”

That claim comes from the Sikiric group.² Patent data on the acetate form in artificial gastric juice show rapid breakdown at pH 2 to 3.⁴ At best, the question is unsettled.

“Myth: Arginate means it’s absorbed orally.”

The arginine salt shows better heat and water stability in the patent data, but absorption was predicted, not measured.⁴

“Myth: Oral is the safe, gentle option.”

No route of BPC-157 has meaningful human safety data. The only formal safety pilot was IV, in two people.^9,13

“Myth: Capsules are a legal supplement in Canada.”

We are not aware of any BPC-157 product with a Canadian NPN or DIN, and Health Canada lists BPC-157 among seized unauthorized products.¹⁵ In the US, it is explicitly not a dietary ingredient.¹⁴

“Myth: It’s a gut peptide, so it only works in the gut.”

The rodent literature covers tendon, ligament and muscle too, mostly with systemic or local delivery.⁸ “Gastric origin” describes where it was found, not where it acts.

For researchers

If your question is about route effects, the published literature gives you a starting map: oral and intraperitoneal comparisons in gut models, systemic and local delivery in musculoskeletal models, and IV and intramuscular PK in rats and dogs. In vitro work sidesteps the bioavailability question entirely, which is one reason cell models remain useful.

TrueLabs supplies BPC-157 as a lyophilized powder in sealed vials only, from $22 CAD, for in vitro and laboratory research. We don’t sell capsules or oral products. Lyophilized powder is a stable format to ship and store. See How to store peptides for temperature and light guidance, and How to read a peptide COA plus the COA library to check identity and purity by batch. If you’re comparing BPC-157 with a copper peptide, see GHK-Cu vs BPC-157.

See BPC-157 →

FAQ

Related reading

• What is BPC-157?
• How to store peptides
• GHK-Cu vs BPC-157
• Is BPC-157 banned?
• BPC-157 side effects
• How to spot fake peptides

References

1. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. PubMed
2. Sikiric P, Boban Blagaic A, Strbe S, et al. The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Pharmaceuticals (Basel). 2024;17(4):461. PubMed
3. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed
4. Rucman R (Diagen d.o.o.). Stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy. US Patent 9,850,282 B2. Granted December 26, 2017. Google Patents
5. Sever M, Klicek R, Radic B, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci. 2009;54(10):2070–2083. PubMed
6. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008;108(1):7–17. PubMed
7. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. 2010. PubMed
8. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PubMed
9. Lee E, Burgess A. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20–24. PubMed
10. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27:8–13. PubMed
11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. UroToday abstract
12. McDermott Will & Emery. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. July 27, 2026. McDermott
13. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495. PubMed
14. Operation Supplement Safety (US Department of Defense). BPC-157: prohibited peptide and unapproved drug found in health and wellness products. April 29, 2025. OPSS
15. Health Canada. Advisory on unauthorized injectable peptide drugs seized and sold in Canada (RA-77807). Recalls and safety alerts, August 1, 2025. Health Canada

This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.